MacuCLEAR, Inc. To Begin Phase III Study of its Lead Compound for Early-Stage Age-Related Macular Degeneration (AMD) –

The active ingredient of MC-1101 has been previously approved by the FDA as an oral antihypertensive drug. MC-1101 has been granted 505 (b) 2 status and has formal Fast Track designation by the FDA. In addition to MC-1101, MacuCLEAR’s portfolio includes 11 …

Leave a Reply

Your email address will not be published. Required fields are marked *